Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, is it all about immunoglobulins?

Proteomics - Clinical Applications

Volumn 4, Issue 4, 2010, Pages 372-378

  Klein, André ^a,b   Michalski, Jean Claude ^b   Morelle, Willy ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

Glycosylation; Liver diseases; N glycome

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; N GLYCOME; PROTEIN; UNCLASSIFIED DRUG;

CONCENTRATION (PARAMETERS); DISEASE MARKER; GLYCOSYLATION; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; PROTEIN SECRETION; REVIEW;

EID: 77953797887     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900151     Document Type: Review

References (33)

1. Klein, A., Human total serum N-glycome. Adv. Clin. Chem. 2008, 46, 51-85.
2. Callewaert, N., Van Vlierberghe, H., Van Hecke, A., Laroy, W. et al., Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004, 4, 429-434.
3. Morelle, W., Flahaut, C., Michalski, J. C., Louvet, A. et al., Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006, 4, 281-293.
4. Carre, Y., Klein, A., Mathurin, P., Michalski, J. C. et al., Changes in serum-associated fucosylated glycoproteins and changes in glycosylation of IgA in human cirrhosis. Proteomics Clin. Appl. 2009, 3, 609-622.
5. Klein, A., Carre, Y., Louvet, A., Michalski, J. C., Morelle, W., Immunoglobulins are the major glycoproteins involved in the modifications of total serum N-glycome in cirrhotic patients. Proteomics Clin. Appl. 2010, 4, this issue, DOI: 10.1002/prca.200900133.
6. Paradis, V., Glycomics: a new taste of cirrhosis marker. J. Hepatol. 2005, 43, 913-914.
7. Becker, W., Variations of immunoglobulins in disease. J. Clin. Pathol. 1975, 6, 92-101.
8. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. et al., The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25, 21-50.
9. Huhn, C., Selman, M. H., Ruhaak, L. R., Deelder, A. M. et al., IgG glycosylation analysis. Proteomics 2009, 9, 882-913.
10. Galili, U., The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell Biol. 2005, 83, 674-686.
11. Mehta, A. S., Long, R. E., Comunale, M. A., Wang, M. et al., Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J. Virol. 2008, 82, 1259-1270.
12. Thiele, G. M., Freeman, T. L., Klassen, L. W., Immunologic mechanisms of alcoholic liver injury. Semin. Liver Dis. 2004, 24, 273-287.
13. Kaneko, Y., Nimmerjahn, F., Ravetch, J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313, 70-73.
14. Mehta, A., Block, T. M., Fucosylated glycoproteins as markers of liver disease. Dis. Markers 2008, 25, 259-265.
15. Roos, A., Bouwman, L. H., van Gijlswijk-Janssen, D. J., Faber-Krol, M. C. et al., Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 2001, 167, 2861-2868.
16. Rifai, A., Fadden, K., Morrison, S. L., Chintalacharuvu KR. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J. Exp. Med. 2000, 191, 2171-2182.
17. González-Quintela, A., López-Ben, S., Pérez, L. F., Graña, B. et al., Time-course changes of serum immunoglobulins (IgA, IgG, IgM) after liver transplantation for alcoholic cirrhosis. Transpl. Immunol. 2003, 11, 73-77.
18. Yamashita, K., Koide, N., Endo, T., Iwaki, Y. et al., Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma. J. Biol. Chem. 1989, 264, 2415-2423.
19. Mori, S., Aoyagi, Y., Yanagi, M., Suzuki, Y. et al., Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1998, 13, 610-619.
20. Miyoshi, E., Ihara, Y., Nishikawa, A., Saito, H. et al., Gene expression of N-acetylglucosaminyltransferases III and V: a possible implication for liver regeneration. Hepatology 1995, 22, 1847-1855.
21. Choi, B. I., Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis. J. Korean Med. Sci. 1998, 13, 103-116.
22. Miyoshi, E., Nakano, M., Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008, 8, 3257-3262.
23. Breborowicz, J., Mackiewicz, A., Breborowicz, D., Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand. J. Immunol. 1981, 14, 15-20.
24. Naitoh, A., Aoyagi, Y., Asakura, H., Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1999, 14, 436-445.
25. Miyoshi, E., Moriwaki, K., Nakagawa, T., Biological function of fucosylation in cancer biology. J. Biochem. 2008, 143, 725-729.
26. Nakagawa, T., Uozumi, N., Nakano, M., Mizuno-Horikawa, Y. et al., Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J. Biol. Chem. 2006, 281, 29797-29806.
27. Poynard, T., Morra, R., Ingiliz, P., Imbert-Bismut, F. et al., Biomarkers of liver fibrosis. Adv. Clin. Chem. 2008, 46, 131-160.
28. Vanderschaeghe, D., Laroy, W., Sablon, E., Halfon, P. et al., GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol. Cell. Proteomics 2009, 8, 986-994.
29. Liu, X. E., Desmyter, L., Gao, C. F., Laroy, W. et al., N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007, 46, 1426-1435.
30. Tanabe, K., Deguchi, A., Higashi, M., Usuki, H. et al., Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients. Biochem. Biophys. Res. Commun. 2008, 374, 219-225.
31. Goldman, R., Ressom, H. W., Varghese, R. S., Goldman, L. et al., Detection of hepatocellular carcinoma using glycomic analysis. Clin. Cancer Res. 2009, 15, 1808-1813.
32. Taketa, K., Sekiya, C., Namiki, M., Akamatsu, K. et al., Lectinreactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990, 99, 508-518.
33. Blomme, B., Van Steenkiste, C., Callewaert, N., Van Vlierberghe, H., Alteration of protein glycosylation in liver diseases. J. Hepatol. 2009, 50, 592-603.